NCT01659346

Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.

A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis

• Status: Withdrawn
• Phase: N/A
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Institute of Liver and Biliary Sciences, India · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic variceal ligation. They will be followed to assess the rate of reduction of index bleed rate as well as survival difference between the groups.

Conditions

• Hepatocellular Carcinoma With Portal Vein Thrombosis

Interventions

Type	Name	Description
PROCEDURE	Endoscopic Variceal Ligation	Endoscopic Variceal Ligation every 3 weeks till eradication.
DRUG	Carvedilol	Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD

Timeline

• Start date: 2016-02-01
• Primary completion: 2017-12-01
• Completion: 2017-12-01
• First posted: 2012-08-07
• Last updated: 2017-11-17

Locations

1 site across 1 country: India